This activity is specifically designed for:
Policy makers
At the end of the course, learners should be able to:
Describe the value of diagnostics in clinical decision making and disease control for COVID-19 and other diagnostics for diseases of public health importance
Accelerate policy development by collaborating with different stakeholders to assess acceptable risks as a trade-off for incremental patient or societal benefits in the use of diagnostic tests
Participate in a community of practice to share best practices and updates on evidence to inform policy
Testing strategies and policy development have become increasingly complex and for the COVID-19 pandemic, there is limited time to conduct research to inform policy. Addressing these issues, the agenda is as follows:
Measurements of diagnostic test performance and use of predictive values
Difference between evaluation, validation and verification
Key considerations in policy development for diagnostic tests for COVID-19 and other infectious diseases
Professor Rosanna Peeling, London School of Hygiene & Tropical Medicine, UK
Professor David Heymann, London School of Hygiene & Tropical Medicine, UK
Dr. Noah Fongwen, London School of Hygiene and Tropical Medicine & Africa CDC, UK
Scott Chiossi, Chatham House, UK
Carlos Gouvea, Latin American Alliance for In Vitro Diagnostic Development (ALADDiV), Brazil
Dr. Sidney Yee, DxD Hub, Association of Southeast Asian Nations (ASEAN), Singapore
Dr. Jaime Montoya, Council for Health Research and Development, Association of Southeast Asian Nations (ASEAN), Philippines
Add your email to the mailing list to get the latest updates.
